Craif Raises $33M Series D to Accelerate U.S. Expansion of Urine-Based Cancer Testing

Craif Raises $33 Million Series D to Accelerate U.S. Expansion of Urine-Based Cancer Testing

Tokyo-based bio-AI company Craif has raised approximately $33 million in Series D funding to strengthen its U.S. R&D, advance clinical development, and prepare for the introduction of its non-invasive cancer testing technology in the United States.

The round was co-led by Granite-Integral, a joint venture between Granite Asia and Integral Corporation, and Tauns Co., Ltd., with participation from Unreasonable, existing investor X&KSK, and other institutional and individual investors.

The financing includes approximately $30.7 million in equity and $3.3 million in debt, bringing Craif's total capital raised since its founding to approximately $88 million.

Building AI-Powered Cancer Detection

Founded in Japan in 2018 by Ryuichi Onose and Takao Yasui, Craif develops urine-based diagnostic technology that uses AI to analyze microRNA, small regulatory molecules associated with biological processes and disease.

The company's flagship miSignal test is already available across more than 2,500 medical institutions and 4,500 pharmacies in Japan, with more than 110,000 tests performed to date.

Craif has also published more than 90 peer-reviewed papers and conference presentations, including research focused on the early detection of pancreatic cancer.

Expanding Into the U.S.

Craif is using the new funding to expand its U.S. R&D operations and prepare for a reimbursement-driven launch of its non-invasive cancer testing technology.

The company opened a bio-AI laboratory in San Diego in April 2026, while CEO and co-founder Ryuichi Onose relocated to San Diego to lead the company's U.S. operations.

Craif is also advancing a prospective clinical study focused on pancreatic cancer and preparing a Japanese regulatory filing for a software-based medical device program targeting pancreatic cancer diagnosis.

Strengthening Its Clinical Team

Craif has appointed Nicholas (Nick) Bevins, MD, PhD, as chief medical officer to lead its clinical development strategy.

Bevins brings experience across clinical pathology, laboratory medicine, diagnostics, and biotechnology, including previous roles as chief medical officer and CLIA laboratory director.

The company is also developing partnerships with medical institutions across the United States as it builds the clinical evidence needed for regulatory approval and reimbursement.

From Japan to the U.S.

Craif's strategy goes beyond a single cancer test. The company is building a broader urine analysis platform designed to identify early biological signals associated with multiple diseases.

With its Japanese commercial base, expanding U.S. clinical operations, and new Series D funding, Craif is now focused on translating its urine-based bio-AI technology into the U.S. healthcare market.